Nuclear Receptors: The Pipeline Outlook Report - Tables and Figures

 

Author: Mark C. Via

FIGURES
Figure 1.1. Mechanism of Class I Nuclear Receptor Action
Figure 1.2. Mechanism of Class II Nuclear Receptor Action
Figure 5.1. Drug Targets as Families
Figure 5.2. Distribution of Trial Types Involving Nuclear Receptor Targets Betweennon-NCE’s
(Figure 5.2A) and NCE’s (Figure 5.2B)

TABLES
Table 1.1. The Classification System for the Nuclear Receptors
Table 2.1. Natural Ligands of Nuclear Receptors and Diseases Associated with Receptor Dysfunction
Table 3.1. TR-beta Agonists in Clinical Trials
Table 3.2. RAR Agonists in Clinical Trials
Table 3.3. PPAR Agonists in Clinical Trials
Table 3.4. LXR/FXR Agonists in Clinical Trials
Table 3.5. VDR Activators in Clinical Trials
Table 3.6. ER Modulators in Clinical Trials
Table 3.7. GR Modulators in Clinical Trials
Table 3.8. PR Modulators in Clinical Trials
Table 3.9. AR Modulators in Clinical Trials
Table 4.1. Worldwide Sales of Nuclear Receptor Drugs Ranked in Top 200 ofAll Drugs, 2009
Table 4.2. Nuclear Receptor-Targeted New Chemical Entities in Late-Stage Development
Table 5.1. Sales Revenue for the Top Nuclear Receptor-Targeted Drugs 
Table 5.2. Total Sales of Top 15 Nuclear Receptor Targeted Drugs by Company
Table 5.3. Percentage of Sales Revenue Generated by Nuclear Receptor-Targeted Drugs
Table 5.4. Drug Companies with Nuclear Receptor-Targeted NCE’s in Development
Table 5.5. Therapy Descriptions for Nuclear Receptor-Targeted Drug Candidates in Development
Table 5.6. Names of Nuclear Receptor Targets and Number of Development Programs
Table 5.7. Top Pipeline Drug Candidates
Table 5.8. Established Nuclear Receptor Targets and New Therapy Applications
Table 5.9. Distribution of Therapeutic Indications between Launched and Pipeline Programs
Table 5.10. Therapeutic Indications and NCE Activity